The Detection of WT1 Gene Expression in Peripheral Blood of Acute Lymphocytic Leukemia Patients Using Real Time RT-PCR Method
Zhihua Guo
Abstract
Zhihua Guo
Abstract
Objective:To establish a real time reverse transcription polymerase chain reaction method for detecting WT1 and to comprehend the expression levels of WT1 in chronic myeloid leukemia (CML) through examining peripheral blood of leuk emia patients.Method:39 CML patients, 26 non-leukemia patients and 16 normal human were included in this study. The method of real time RT-PCR detecting the expression of WT1 was established. The expresion levels of WT1 gene were tested using this method.Results:The expression levels of WT1 in 5 blastic crisis of CML patients were (312 000±126 965)copies/μg RNA, those of 19 within accelerat ed phase were (18 652±22 879)copies/μg, and those of 15 within chronic phase were (154±182)copies/μgRNA.Conclusion:Expression of WT1 in CML were sigificantly higher than that in non-leukemias and normal human . WT1 could be a marker for detecting minimal residual dis ease and evaluating therapeutic efficacy in CML.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Objective:To establish a real time reverse transcription polymerase chain reaction method for detecting WT1 and to comprehend the expression levels of WT1 in chronic myeloid leukemia (CML) through examining peripheral blood of leuk emia patients.Method:39 CML patients, 26 non-leukemia patients and 16 normal human were included in this study. The method of real time RT-PCR detecting the expression of WT1 was established. The expresion levels of WT1 gene were tested using this method.Results:The expression levels of WT1 in 5 blastic crisis of CML patients were (312 000±126 965)copies/μg RNA, those of 19 within accelerat ed phase were (18 652±22 879)copies/μg, and those of 15 within chronic phase were (154±182)copies/μgRNA.Conclusion:Expression of WT1 in CML were sigificantly higher than that in non-leukemias and normal human . WT1 could be a marker for detecting minimal residual dis ease and evaluating therapeutic efficacy in CML.
Key concepts: Medicine, Real-time polymerase chain reaction, Myeloid leukemia, Minimal residual disease, Leukemia, Reverse transcription polymerase chain reaction, Peripheral blood, breakpoint cluster region